Improving selective androgen receptor modulator discovery and preclinical evaluation

Expert Opinion on Drug Discovery

Volumn 4, Issue 9, 2009, Pages 981-993

  Jones, Jeremy Orion ^a  

^a Genentech Hall ^*  (United States)

Author keywords

Androgen replacement therapy; AR; Prostate cancer; SARM

Indexed keywords

ANDROGEN; ANDROSTANOLONE; BICALUTAMIDE; OSTARINE; S 40503; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; BONE DENSITY; CASTRATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; HORMONE ACTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN EXPRESSION; REVIEW; SEXUAL FUNCTION; TISSUE DISTRIBUTION;

EID: 70249141677     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903206957     Document Type: Review

References (91)

1. Katzenellenbogen JA, Katzenellenbogen BS. Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem Biol 1996;3(7):529-536
2. Georget V, Terouanne B, Nicolas JC, Sultan C. Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 2002;41(39):11824-11831
3. Schaufele F, Carbonell X, Guerbadot M, et al. The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci USA 2005;102(28):9802-9807 (Pubitemid 40993649)
4. Jones JO, Diamond MI. A cellular conformation-based screen for androgen receptor inhibitors. ACS Chem Biol 2008;3(7):412-418
5. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20(13):3001-3015
6. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23(32):8253-8261
7. Sar M, Lubahn DB, French FS, Wilson EM. Immunohistochemical localization of the androgen receptor in rat and human tissues. Endocrinology 1990;127(6):3180-3186
8. Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Front Biosci 1996;1:d59-71
9. Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol 2001;179(1-2):105-109
10. Pucci E, Petraglia F. Treatment of androgen excess in females: yesterday, today and tomorrow. Gynecol Endocrinol 1997;11(6):411-433 (Pubitemid 28029584)
11. Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes 2009;16(3):246-253
12. Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 2004;14(3):177-183 (Pubitemid 38582317)
13. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007;14(3):247-254 (Pubitemid 46684481)
14. Sprenkle PC, Fisch H. Pathologic effects of testosterone deprivation. Curr Opin Urol 2007;17(6):424-430
15. Tostain JL, Blanc F. Testosterone deficiency: a common, unrecognized syndrome. Nat Clin Pract Urol 2008;5(7):388-396 (Pubitemid 352003294)
16. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-39 (Pubitemid 38524696)
17. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8(4):440-448 (Pubitemid 351798756)
18. Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease. Urol Oncol 2009;27(3):251-257
19. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6(2):76-85
20. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68(11):4447-4454
21. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001;23(9):1355-1390
22. Ball LJ, Levy N, Zhao X, et al. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements. Mol Cell Endocrinol 2009;299(2):204-211
23. Jordan VC. The science of selective estrogen receptor modulators: concept to clinical practice. Clin Cancer Res 2006;12(17):5010-5013
24. Levy N, Tatomer D, Herber CB, et al. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Mol Endocrinol 2008;22(2):287-303 (Pubitemid 351185932)
25. McDonnell DP, Wijayaratne A, Chang CY, Norris JD. Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. Am J Cardiol 2002;90(1A):35F-43F (Pubitemid 34775151)
26. Gould DC, Kirby RS. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? Prostate Cancer Prostatic Dis 2006;9(1):14-18
27. Gerber AN, Masuno K, Diamond MI. Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc Natl Acad Sci USA 2009;106(12):4929-4934
28. Amler LC, Agus DB, Leduc C, et al. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res 2000;60(21):6134-6141
29. Nelson PS, Clegg N, Arnold H, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002;99(18):11890-11895 (Pubitemid 34994494)
30. Velasco AM, Gillis KA, Li Y, et al. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 2004;145(8):3913-3924 (Pubitemid 39037580)
31. Kazmin D, Prytkova T, Cook CE, et al. Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol Endocrinol 2006;20(6):1201-1217 (Pubitemid 43801226)
32. Norris JD, Joseph JD, Sherk AB, et al. Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. Chem Biol 2009;16(4):452-460
33. Agoulnik IU, Weigel NL. Coactivator selective regulation of androgen receptor activity. Steroids 2009;74(8):669-674
34. Bebermeier JH, Brooks JD, DePrimo SE, et al. Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription. J Mol Med 2006;84(11):919-931 (Pubitemid 44655870)
35. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001;104(5):719-730 (Pubitemid 32241022)
36. Lutz LB, Jamnongjit M, Yang WH, et al. Selective modulation of genomic and nongenomic androgen responses by androgen receptor ligands. Mol Endocrinol 2003;17(6):1106-1116 (Pubitemid 36683718)
37. Narayanan R, Coss CC, Yepuru M, et al. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol 2008;22(11):2448-2465
38. Droz JP, Kattan J, Bonnay M, et al. High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer. Cancer 1993;71(Suppl 3):1123-1130 (Pubitemid 23049640)
39. Narayanan R, Mohler ML, Bohl CE, et al. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal 2008;6:e010
40. Maynard PV, Cameron EH. Metabolism of androst-4-ene-3,17-dione by subcellular fractions of rat adrenal tissue with particular reference to microsomal C19-steroid 5alpha-reductase. Biochem J 1973;132(2):283-291
41. Hershberger LG, Shipley EG, Meyer RK. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953;83(1):175-180
42. Furr BJ. The development of Casodex (bicalutamide): preclinical studies. Eur Urol 1996;29(Suppl 2):83-95 (Pubitemid 26118368)
43. Kolvenbag GJ, Blackledge GR, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 1998;34(1):61-72 (Pubitemid 28023827)
44. Mohler ML, Bohl CE, Jones A, et al. Nonsteroidal Selective Androgen Receptor Modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 2009;52(12):3597-3617
45. Plank LD. Dual-energy X-ray absorptiometry and body composition. Curr Opin Clin Nutr Metab Care 2005;8(3):305-309 (Pubitemid 40586190)
46. Ruizeveld de Winter JA, Trapman J, Vermey M, et al. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem 1991;39(7):927-936
47. Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br J Pharmacol 2008;154(3):522-528 (Pubitemid 351744946)
48. Windahl SH, Galien R, Chiusaroli R, et al. Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor. J Clin Invest 2006;116(9):2500-2509 (Pubitemid 44330149)
49. Yin D, Gao W, Kearbey JD, et al. Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 2003;304(3):1334-1340 (Pubitemid 36254449)
50. Hanada K, Furuya K, Yamamoto N, et al. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull 2003;26(11):1563-1569 (Pubitemid 41699636)
51. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999;84(10):3459-3462 (Pubitemid 30645191)
52. Zhang X, Lanter JC, Sui Z. Recent advances in the development of selective androgen receptor modulators. Expert Opin Ther Pat 2009, doi: 10.1517/13543770902994397, PMID: 19505196, [In press]
53. Jones JO, An WF, Diamond MI. AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. ACS Chem Biol 2009;4(3):199-208
54. Jones JO, Bolton EC, Huang Y, et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci USA 2009;106(17):7233-7238
55. Mellinghoff IK, Vivanco I, Kwon A, et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6(5):517-527 (Pubitemid 39469987)
56. Tindall DJ, Chang CH, Lobl TJ, Cunningham GR. Androgen antagonists in androgen target tissues. Pharmacol Ther 1984;24(3):367-400
57. Weinbauer GF, Jackwerth B, Yoon YD, et al. Pharmacokinetics and pharmacodynamics of testosterone enanthate and dihydrotestosterone enanthate in non-human primates. Acta Endocrinol (Copenh) 1990;122(4):432-442 (Pubitemid 20138050)
58. Wilson JD, Leihy MW, Shaw G, Renfree MB. Androgen physiology: unsolved problems at the millennium. Mol Cell Endocrinol 2002;198(1-2):1-5 (Pubitemid 36169928)
59. Soderholm AA, Lehtovuori PT, Nyronen TH. Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain. J Med Chem 2005;48(4):917-925
60. Imai Y, Kondoh S, Kouzmenko A, Kato S. Regulation of bone metabolism by nuclear receptors. Mol Cell Endocrinol 2008, doi:10.1016/j.mce.2008.08.015, PMID: 18789372, [In presss]
61. Vanderschueren D, Vandenput L, Boonen S, et al. Androgens and bone. Endocr Rev 2004;25(3):389-425
62. Burtea C, Lefter C, Butnaru F, David A. Steroid hormones control on nucleic acid biosynthesis in skeletal muscle. Rom J Endocrinol 1992;30(3-4):109-114
63. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008;154(3):502-521
64. McEwen BS. Steroid hormones and the brain: cellular mechanisms underlying neural and behavioral plasticity. Psychoneuroendocrinology 1980;5(1):1-11
65. Shah NM, Pisapia DJ, Maniatis S, et al. Visualizing sexual dimorphism in the brain. Neuron 2004;43(3):313-319
66. Strum SB, McDermed JE, Scholz MC, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79(6):933-941
67. Bjorntorp P. Hormonal control of regional fat distribution. Hum Reprod 1997;12(Suppl 1):21-25
68. Soreide JA, Lea OA, Varhaug JE, et al. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 1992;18(2):112-118
69. Lovely LP, Appa Rao KB, Gui Y, Lessey BA. Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem Mol Biol 2000;74(4):235-241 (Pubitemid 32121659)
70. Walters KA, Allan CM, Handelsman DJ. Androgen actions and the ovary. Biol Reprod 2008;78(3):380-389
71. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001;37(5):1199-1208 (Pubitemid 34163570)
72. Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 2002;16(10):2181-2187 (Pubitemid 35155532)
73. Losel RM, Feuring M, Falkenstein E, Wehling M. Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids 2002;67(6):493-498 (Pubitemid 34311765)
74. Pereira S, Martinez M, Martinez FE, Junior WM. Repercussions of castration and vasectomy on the ductal system of the rat ventral prostate. Cell Biol Int 2006;30(2):169-174 (Pubitemid 43259433)
75. Sugimura Y, Cunha GR, Donjacour AA. Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. Biol Reprod 1986;34(5):973-983 (Pubitemid 17190602)
76. Chandolia RK, Weinbauer GF, Behre HM, Nieschlag E. Evaluation of a peripherally selective antiandrogen (Casodex) as a tool for studying the relationship between testosterone and spermatogenesis in the rat. J Steroid Biochem Mol Biol 1991;38(3):367-375
77. Hu LY, Du D, Hoffman J, et al. (1R,2S)-4-(2-cyano-cyclohexyl-oxy)-2- trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production. Bioorg Med Chem Lett 2007;17(21):5983-5988 (Pubitemid 47449746)
78. Ustunel I, Akkoyunlu G, Demir R. The effect of testosterone on gastrocnemius muscle fibres in growing and adult male and female rats: a histochemical, morphometric and ultrastructural study. Anat Histol Embryol 2003;32(2):70-79 (Pubitemid 37249035)
79. Miner JN, Chang W, Chapman MS, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology 2007;148(1):363-373 (Pubitemid 46021469)
80. Goss PE, Qi S, Hu H, Cheung AM. The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model. Breast Cancer Res Treat 2007;103(3):293-302 (Pubitemid 46944512)
81. Jones A, Chen J, Hwang DJ, et al. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2- hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology 2009;150(1):385-395
82. Kearbey JD, Gao W, Narayanan R, et al. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res 2007;24(2):328-335 (Pubitemid 46084804)
83. Gao W, Reiser PJ, Coss CC, et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005;146(11):4887-4897 (Pubitemid 41446627)
84. Gao W, Kearbey JD, Nair VA, et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 2004;145(12):5420-5428 (Pubitemid 39564578)
85. Hamann LG, Manfredi MC, Sun C, et al. Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators. Bioorg Med Chem Lett 2007;17(7):1860-1864 (Pubitemid 46367685)
86. Ostrowski J, Kuhns JE, Lupisella JA, et al. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007;148(1):4-12 (Pubitemid 46023448)
87. Martinborough E, Shen Y, Oeveren A, et al. Substituted 6-(1-pyrrolidine) quinolin-2(1H)-ones as novel selective androgen receptor modulators. J Med Chem 2007;50(21):5049-5052 (Pubitemid 47585701)
88. Allan G, Lai MT, Sbriscia T, et al. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats. J Steroid Biochem Mol Biol 2007;103(1):76-83 (Pubitemid 44821817)
89. Allan GF, Tannenbaum P, Sbriscia T, et al. A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine 2007;32(1):41-51 (Pubitemid 350242546)
90. Trump RP, Blanc JB, Stewart EL, et al. Design and synthesis of an array of selective androgen receptor modulators. J Comb Chem 2007;9(1):107-114
91. Piu F, Gardell LR, Son T, et al. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. J Steroid Biochem Mol Biol 2008;109(1-2):129-137